| Lineage |
Glia > Oligodendrocyte > Disease-Associated |
| Markers |
OLIG2, MBP, PLP1, SOX10, MAG |
| Brain Regions |
White Matter, Cortical Gray Matter, Subcortical Structures |
| Disease Associations |
Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, ALS, White Matter Lesions |
| Key Functions |
Myelin Maintenance, Metabolic Support, Iron Homeostasis |
Disease Associated Oligodendrocytes plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Disease-Associated Oligodendrocytes (DOLOs) represent a distinct oligodendrocyte state that emerges in response to CNS pathology. First characterized through single-cell RNA sequencing in mouse models of multiple sclerosis and Alzheimer's disease, DOLOs represent a continuum of oligodendrocyte responses to injury, infection, and neurodegeneration[1].
Unlike the classical view of oligodendrocytes as passive myelin-producing cells, DOLOs demonstrate that oligodendrocyte lineage cells are highly responsive to their microenvironment and can adopt diverse phenotypes depending on the nature and duration of pathological stimuli.
¶ Identification and Markers
DOLOs are identified by a unique transcriptional signature that differs from both mature oligodendrocytes and oligodendrocyte precursor cells (OPCs):
- OLIG2: Transcription factor driving oligodendrocyte lineage specification
- MBP (Myelin Basic Protein): Structural myelin protein (may be downregulated)
- PLP1 (Proteolipid Protein 1): Major myelin protein
- SOX10: Master regulator of oligodendrocyte development
- MAG (Myelin-Associated Glycoprotein): Cell adhesion molecule
- CSPG4 (NG2): Increased expression in reactive oligodendrocytes
- CD44: Hyaluronic acid receptor, upregulated in demyelination
- VCAM1: Adhesion molecule induced by inflammation
- CXCR4: Chemokine receptor involved in OPC recruitment
Oligodendrocytes extend processes that wrap around multiple axons, forming the multilamellar myelin sheath that:
- Enables saltatory conduction (10-100x faster than unmyelinated axons)
- Provides metabolic support to axons through the perinodal space
- Reduces axonal diameter through compaction
- Segregates potassium channels at nodes of Ranvier
Oligodendrocytes provide critical metabolic support to axons:
- Lactate transport: Deliver glycolytic metabolites via MCT1
- Pyruvate recycling: Support mitochondrial function
- Glutamine synthesis: Provide precursor for neurotransmitter synthesis
Oligodendrocytes are the brain's primary iron-storing cells:
- Ferritin expression for iron sequestration
- Transferrin for iron delivery to neurons
- Iron release during demyelination contributes to oxidative stress
In response to acute demyelination, oligodendrocytes:
- Dedifferentiate: Lose myelin gene expression
- Migrate: OPCs proliferate and migrate to lesion sites
- Remyelinate: Form thinner, shorter myelin sheaths (shadow remyelination)
- Secrete factors: Release trophic molecules supporting axons
Prolonged disease leads to the DOLO phenotype:
- Myelin gene downregulation: Reduced MBP, PLP1 expression
- Stress response activation: HSPs, chaperones upregulated
- Immune modulation: Secretion of cytokines and complement proteins
- Metabolic dysfunction: Impaired lactate transport, mitochondrial stress
In MS, oligodendrocytes are both targets and responders:
Pathological features:
- Active lesions: Oligodendrocyte death, demyelination
- Shadow lesions: Partial remyelination
- Chronic lesions: Oligodendrocyte depletion
DOLO characteristics in MS:
- Present in chronic active lesions
- Express immune modulatory genes
- May contribute to repair failure
- Correlation with disability progression
White matter abnormalities in AD involve oligodendrocyte dysfunction:
Contributing factors:
- Amyloid deposition in white matter
- Ischemic damage to oligodendrocytes
- Tau pathology in oligodendrocytes
- Impaired glucose metabolism
DOLO in AD:
- Upregulation of stress response genes
- Altered myelin gene expression
- Contribution to white matter hyperintensities on MRI
Oligodendrocyte involvement in PD:
- α-Synuclein inclusions in oligodendrocytes (MSA-like pathology)
- White matter changes in prodromal PD
- Impaired iron handling contributes to neurodegeneration
In ALS:
- White matter degeneration precedes clinical symptoms
- Oligodendrocyte precursor dysfunction
- Reduced myelin protein expression
- Metabolic support failure
- OPC promotion: Medications that enhance OPC differentiation (e.g., benztropine, clemastine)
- Block inhibitors: Anti-Lingo-1 antibodies promote remyelination
- Growth factors: BDNF, PDGF delivery to support oligodendrocytes
- Cell therapy: OPC transplantation approaches
- Metabolic support: Enhance lactate transport (MCT1 agonists)
- Iron chelation: Deferoxamine to reduce oxidative stress
- Anti-inflammatory: Reduce microglial activation
- Mitochondrial protectants: CoQ10, idebenone
- Target DOLO conversion: Shift from disease-associated to healthy state
- Myelin repair: Enhance myelin gene expression
- Axonal support: Maintain axonal integrity
Disease Associated Oligodendrocytes plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Disease Associated Oligodendrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Jäkel S, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019
-
Masis F, et al. Disease-associated oligodendrocytes in Alzheimer's disease and multiple sclerosis. Nat Neurosci. 2019
-
Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol. 2010
-
Simons M, Nave KA. Oligodendrocytes: Myelin formation and maintenance. Neuron. 2015
-
Morrison BM, et al. Oligodendrocyte development and the etiology of multiple sclerosis. Nat Med. 2013
-
Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012